Top News – PsychedelicsFN

PhamaTher Selects Partner for Clinical & Commercial Manufacturing of Its Ketamine Products

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, recently announced that it has signed a contract with Alcami Corporation, a global pharmaceutical contract development and manufacturing…

Levitee Labs Partners with Adracare to Support Addiction, Mental Health Treatments

Adracare Inc. (“Adracare”), a Well Health Technologies company (TSX: WELL), recently announced a partnership with Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7), an integrative wellness company with a…

Cybin Completes 74 Pre-Clinical Studies, Plans Event to Review Findings

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biotechnology company focused on the advancement of psychedelic therapeutics, recently announced the completion of its 74th pre-clinical study as part of its ongoing efforts…

Psyched Wellness Finds Potential New Functional Property & Health Benefits in Preliminary Data

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9), a life sciences company focused on artisanal functional and psychedelic mushrooms, recently found a new potential functional property and health benefit…

Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased…

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to have finalized the study design and protocol for a Phase 1 clinical…

PsyBio Reports Significant Progress in Second Quarter Financial Results

PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF), an intellectual property-driven biotechnology company developing novel formulations of psychoactive drugs produced by genetically modified bacteria and other innovative mediums for the potential…

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training…

atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs

atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest , Australia’s leading university technology transfer company commercializing the research…

Filament Health Corp. Announces Approval for Listing on the NEO Exchange

Filament Health Corp. (“Filament”, the “Company” or the “Resulting Issuer”), an exclusively-natural psychedelic drug discovery and extraction technology company, is pleased to announce it has received final approval to list its…